About Us
loction：home > Typical Case Typical Case
First Chinese electronic enterprise listed in U.S. capital market by IPO
The Aidi team entered the international capital market in 1996. Mr. Du Guanlin, the Chairman of US Aidi Investment Co., Ltd, went on to create a leveraging miracle in directly listing a Chinese company [ which had only ￥70 million RMB sales revenue annually and $5 million net assets] in the U.S. capital market through an IPO，thus consummating over $46 million of external financing, and the market value of the company has reached to $0.1 billion . This company was the first Chinese electric enterprise to list in the U.S. capital market. Mr. Du once again proved the precursor of many modern market trends as he then successfully listed a Chinese company in the U.S. capital market solely through his own endeavors. These events have been reported on CCTV over 18 times to date.
First acquisition of a Japanese corporation by Chinese enterprise ...
In 1997, the company led by President Du acquired a Japanese construction company with 200,000,000 Japanese Yen of net assets by using zero capital. This was the first acquisition of a Japanese enterprise by a Chinese enterprise in Japan. The news that the Japanese Prime Minister, Ryutaro Hashimoto, sent a congratulation message to Mr. Du about this Chinese acquisition was ranked as one of the “Top Ten News Events in China in 1997”.
Joint-Venture, Reverse Merger and listing case
In April 2004, Shandong Weifang Shengtai Pharmaceutical Co., Ltd (“Weifang Shengtai”) was acquired by an American listed company and consequently became a Joint-Venture enterprise. Through this transaction, Weifang Shengtai obtained $2 million cash and some of the American listed company’s preferred stock, valued at $5.36 million, for its 51% stock equity stake. In June 2006, under the guidance of Aidi, Weifang Shengtai bought-back its 51% stock equity for $1.3 million and changed its status to that of WFOE. Afterwards, Aidi further assisted the company in successfully listing in U.S. capital markets through an Alternative Public offering (“APO”), and initially raised some $17.5 million.
Chinese pharmaceutical enterprise with small distribution network ...
In 2006, Guangzhou Konzern Medical Corporation, a Chinese corporation with fixed assets of less than $400,000 was successfully listed in U.S. capital market with Aidi’s stewardship. Konzern’s main business is to distribute medicines relying solely upon marketing, and its sales revenue for 2005 was only around $ 10 million. This is the first case where a Chinese company with such a limited distribution network has been able to gain a listing in the U.S. capital markets.